Reye syndrome: monoamine metabolites in ventricular fluid

Area of Science:

• Neurochemistry
• Pediatric Neurology

Background:

• Reye syndrome is a severe condition affecting children, characterized by encephalopathy and fatty liver.
• Understanding the biochemical alterations in Reye syndrome is crucial for diagnosis and management.

Purpose of the Study:

• To investigate the concentrations of monoamine metabolites, homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), in the cerebrospinal fluid (CSF) of children with Reye syndrome.
• To compare these metabolite levels with those in healthy controls and explore their correlation with clinical parameters.

Main Methods:

• Measurement of HVA and 5-HIAA concentrations in CSF samples from 15 children with Reye syndrome and 7 control children using established analytical techniques.
• Analysis of serial CSF samples to observe fluctuations in metabolite levels.
• Correlation analysis between metabolite concentrations and clinical data including serum ammonia, intracranial pressure, morbidity, and mortality.

Main Results:

• Homovanillic acid (HVA) levels were markedly elevated in Reye syndrome patients (median, 887 ng/mL) compared to controls (median, 282 ng/mL).
• 5-hydroxyindoleacetic acid (5-HIAA) levels were comparable between groups (medians of 198 ng/mL and 189 ng/mL, respectively).
• The ratio of 5-HIAA to HVA was significantly lower in Reye syndrome patients (0.26) than in controls (0.51); HVA showed wide fluctuations, while 5-HIAA remained stable.

Conclusions:

• Elevated HVA in Reye syndrome suggests potential cerebral ischemia and increased dopamine release into the brain and CSF.
• The altered HVA/5-HIAA ratio may serve as a biomarker for Reye syndrome.
• Monoamine metabolite concentrations did not correlate with clinical severity, indicating a complex pathophysiology.